NAME
POSITION TITLE
Michael Jensen
Professor
eRA COMMONS USER NAME (credential, e.g., agency
login)
Michaeljensen
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include
postdoctoral training.)
INSTITUTION AND LOCATION
DEGREE
(if applicable)
MM/YY
FIELD OF STUDY
Tufts University, Medford
B.S.
05/86
Biology
University of Pennsylvania,
Philadelphia
M.D.
05/90
Medicine
Children's Hospital of N. Calif.,
Oakland
Residency
06/93
Pediatrics
Univ. of WA/FHCRC, Seattle
Fellowship
07/97
Peds. HemOnc/BMT
A. Personal Statement
My role as a lead investigator on the “Pediatric Leukemia Adoptive Therapy (PLAT)-01”
Phase I clinical study will be to facilitate the clinical translation of advances in T cell genetic
engineering to improve the prognosis of children with relapsed acute lymphoblastic
leukemia. Building on my laboratory’s preclinical modeling, cGMP process development,
and clinical experience in early phase IND supported T cell adoptive therapy trials, I will
support the translational and clinical activities proposed in this study. My clinical training in
pediatric hematology-oncology and hematopoietic cell transplantation in Seattle and
laboratory research training under the mentorship of Dr. Philip D Greenberg at the FHCRC
and extensive collaborative work with Dr. Stan Riddell have provided me the research and
clinical skill set to be an effective investigator on this clinical study. I am currently Director of
the Ben Towne Center for Childhood Cancer at Seattle Children’s Research Institute. In
addition, I hold an appointment at the University of Washington School of Medicine as
Professor of Pediatrics in the Division of Pediatric Hematology-Oncology, with a Joint
Membership to the Fred Hutchinson Cancer Research Center Program in
Immunology. Since establishing an independent research program 13 years ago at City of
Hope, I have lead five FDA-authorized investigator-initiated IND supported human clinical
trials employing genetically modified T-cell adoptive immunotherapy, one of which was a pilot
first-in-human trial using CD19-specific CTL adoptive transfer for follicular lymphoma.
B. Positions and Honors.
Positions and Employment
1993-1997
Fellow, Pediatric Hematology/Oncology, University of Washington/Fred
Hutchinson Cancer Research Center, Seattle, WA (Three year research
component- Program in Immunology, FHCRC/Mentor- Dr. Philip D. Greenberg)
1997-2004
Assistant Professor, Pediatrics, COHNMC, Duarte, CA
2002-2010
Program Leader, Cancer Immunotherapeutics Program, City of Hope NCIdesignated Comprehensive Cancer Center
2004-2009
Associate Professor, Pediatrics, COHNMC
2004-2010
Associate Chairman, Department of Cancer Immunotherapeutics & Tumor
Immunology, Beckman Research Institute at City of Hope
2010-2010
Professor, Pediatrics, COHNMC
2010-present Jim & Jan Sinegal Endowed Professor, Pediatrics, University of Washington
School of Medicine
2010-present Joint Member, Program in Immunology, Fred Hutchinson Cancer Research
Center
2011-Present Associate Head, Program in Immunology and Vaccine Research, UW/FHCRC
NCI-designated Comprehensive Cancer Center
2011-Present Director, Center for Childhood Cancer Research, Seattle Children’s Research
Institute
Other Experience and Professional Memberships
1997-Present Member, American Society for Gene and Cell Therapy
2003-Present Member, Society for Pediatric Research
2005-2010
External Cancer Center Advisory Board, Fred Hutchinson Cancer Research
Center
2006-Present Scientific Advisory Board, Brain Tumor Society
2007-Present CTN SOSS Cell and Gene Therapy Committee
2009-Present External Advisory Board, European Union Framework Programme Six
Integrated Project
2009-Present Scientific Advisory Board, Forbeck Foundation
2010-Present Member, American Pediatric Society
Honors
1998
2003
2009
ASBMT Ernest McCullock and James Till Award
Society for Pediatric Research Young Investigator Award
STOP CANCER Foundation Career Advancement Award
C. Selected peer-reviewed publications (selected from 54 peer reviewed publications)
Most relevant to the current application
1. Cooper, L.N., Topp, M.S., Serrano, L.M., Gonzalez, S., Chang, W.C., Naranjo, A., Wright,
C., Popplewell, L., Raubitschek, A., Forman, S.J., Jensen, M.C.: T-cell clones can be
rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage
leukemia effect. Blood 2003;101(4):1637-44.
2. Chen, Y.C., Jensen, M.C.†, Smolke, C.D.†: Genetic control of mammalian T-cell
proliferation with synthetic RNA regulatory systems. Proc Natl Acad Sci USA
2010;107(19):8531-8536. PMCID: PMC2889348 (†M.C.J. and C.D.S. designated equal
contributors to work as senior authors).
3. Wang, X., Berger, C., Wong, C.W., Forman, S.J., Riddell, S.R., Jensen, M.C.: Engraftment
of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood
2011;117(6):1888-98. PMCID: PMC3056638
4. Wang, X., Chang, C.W., Colcher, D., Sherman, M, Ostberg, J.R., Riddell, S.R., Jensen,
M.C.: A transgene encoded cell surface polypeptide for selection, in vivo tracking, and
ablation of engineered cells. Blood 2011; 118(5):1255-63. PMCID: PMC3152493
5. Terakura, S., Yamamoto, T.N., Gardner, R.A., Turtle, C.J., Jensen, M.C., Riddell, S.R.:
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virusspecific central memory cells. Blood 2011;119(1):72-82. PMCID: PMC3251238
Additional recent publications of importance to the field (in chronological order)
1.
2.
3.
4.
5.
6.
Jensen, M., Tan, G., Forman, S., Wu, A.M., and Raubitschek, A.: CD20 is a molecular
target for scFvFc:z receptor re-directed T cells: implications for cellular immunotherapy of
CD20+ malignancy. Biology of Blood and Marrow Transplantation, 4:75-83, 1998.
Jensen, M. C., Clarke, P., Tan, G., Wright, C., Chung-Chang, W., Clark, T.N. , Zhang, F.,
Slovak, M.L., Wu, A.M., Forman, S.J., and Raubitschek, A.: Human T Lymphocyte genetic
modification with naked DNA. Mol Therapy, 1(1):49-55, 2000.
Jensen, M.C., Cooper, L.J.N., Wu, A.M., Forman, S.J., and Raubitschek, A.: Engineered
CD20-specific primary human cytotoxic T lymphocytes for targeting B-Cell malignancy.
Cytotherapy, 5(2):131-138, 2003.
Wang, J., Press, O.W., Lindgren, C.G., Greenberg, P., Riddell, S., Qian, X., Laugen, C.,
Raubitschek, A., Forman, S.J., and Jensen, M.C.: Cellular immunotherapy for follicular
lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
Molecular Therapy, 9(4) 577-86, 2004.
Cooper, L.J., Al-Kadhimi, Z., DiGiusto, D., Kalos, M., Colcher, D., Raubitschek, A., Forman,
S.J., and Jensen, M.C.: Development and application of CD19-specific T cells for adoptive
immunotherapy of B cell malignancies. Blood Cells, Molecules, & Diseases. 33(1):83-89,
2004.
Cooper, L.J.N., Topp, M.S., Pinzon, C, Jensen, M.C., Riddell, S.R., and Greenberg P.D.:
Enhanced transgene expression in quiescent and activated human CD8+ T cells. Human
Gene Therapy. 15(7):648-58, 2004.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Cooper, L.J.N., Al-Kadhimi, Z., Serrano, L.M., Pfeiffer, T., Olivares, S., Castro, A., Chang,
W.-C., Gonzalez, S., Smith, D., Forman, S.J., and Jensen, M.C.: Enhanced antilymphoma
efficacy of CD19-redirected influenza MP1-specific CTL's by co-transfer of T cells modified
to present influenza MP1. Blood, 105(4):1622-31, 2005.
Serrano, L.M., Pfeiffer, T., Olivares, S. Numbenjapon, T., Bennitt, J., Kim, D., Smith, D.,
McNamara, G., Al-Kadhimi, Z., Rosenthal, J., Forman, S.J. Jensen, M.C. and Cooper,
L.J.: Differentiation of naïve cord blood T cells into CD19-specific cytolytic effectors for
post-transplant adoptive immunotherapy. Blood; 107(7):2643-52, 2006. PMCID:
PMC1895371
Kowolik, C.M., Topp, M.S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith,
D.D., Forman, S., Jensen, M.C., and Cooper, L.J.: CD28 constimulation provided through
a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor
efficacy of adoptively transferred T cells. Cancer Research, 66(22):10995-1004, 2006.
Park, J.R., DiGiusto, D.L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet,
H.B., Bautista, C., Chang, W.C., Ostberg, J.R., and Jensen, M.C.: Adoptive transfer of
chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with
neuroblastoma. Molecular Ther, 15(4):825-33, 2007.
Wang, J., Jensen, M., Lin, Y., Sui, X., Chen, E., Lindgren, C.G., Till, B., Raubitschek, A.,
Forman, S.J., Qian, X., James, S., Greenberg, P., Riddell, S., Press, O.W.: Optimizing
adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor
possessing CD28 and CD137 costimulatory domains. Hu Gene Ther. 18(8):712-25, 2007.
Chang, L., Chang, W.C., McNamara, G., Aguilar, B., Ostberg, J.R., and Jensen, M.C.:
Transgene Enforced Costimulation of CD4+ T cells leads to Enhanced and Sustained AntiTumor Effector Functioning. Cytother., 2007;9:771-84.
Berger, C., Jensen, M.C., Lansdorp, P.M., Gough, M., Elliott, C., Riddell, S.R.: Adoptive
transfer of effector CD8 T cells derived from central memory cells establishes persistent T
cell memory in primates. J. Clin. Investigation, 2008;118(1):294-305. PMCID:
PMC2104476
Jensen, M.C., Popplewell, L., Cooper, L.J., DiGiusto, D., Kalos, M., Ostberg, J.R., Forman,
S.J.: Antitransgene rejection responses contribute to attenuated persistence of adoptively
transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
Biol. Of Blood & Marrow Transplantation, 2010:16(9):1245-56. PMCID: in progress.
Till, B.G., Jensen, M.C., Wang J., Qian, X., Gopal, A.K., Maloney, D.G., Lindgren C.G., Lin,
Y., Pagel, J.M., Budde, L.E., Raubitschek, A., Forman, S.J., Greenberg, P.D., Riddell, S.R.,
Press, O.W.; CD20-specific adoptive immunotherapy for lymphoma using a chimeric
antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood, 2012:
in press.
D. RESEARCH SUPPORT
Ongoing Research Support
5 R01 CA136551-02 Jensen (Co-PI)
07/01/2009-06/30/2014
NIH/NCI
Targeted therapy of ALL with gene-modified central memory T Cells
Specific Aim 1, to determine the safety and anti-tumor activity of adoptive therapy with
donor Tcm-derived bio-specific (CMVpp65xCD19) Te clones for patients with CD19+
ALL following HLA matched allogeneic HCT. Specific Aim 2, to determine the safety and
anti-tumor activity of adoptive therapy with autologous Tcm-derived bi-specific
(CMVpp65xCD19) polyclonal Te cells for patients with CD19+ ALL following autologous
HCT.
Role: Co-PI with Dr. Stanley Riddell, FHCRC
P50 CA107399-05 Forman (PI)
03/01/2012-02/28/2017
NIH/NCI
City of Hope Lymphoma SPORE
This is a Specialized Program of Research Excellence for the development of translation
projects. Project 2 focuses on the development of lymphoma targeting adoptive therapy
using genetically modified CD19-specific T-cells that express second-generation antigen
receptor chimeras having both activation and co-stimulatory modules.
Role: Project Leader